Cannabis Science & Policy Summit - Day 1 - MacCoun
•
0 likes•159 views
This document summarizes key points from Jon's talk on cannabis legalization. It notes that national legalization following an alcohol model is likely. Long-run cannabis consumption may double. Prices and quantity consumed matter more than the number of consumers. There are many policy levers but it is unclear if they are being used effectively to learn what works. National legalization is not guaranteed and effects in states like Colorado are still uncertain due to many complicating factors. The fundamental tradeoff is that legalization may reduce average harm per dose while increasing total doses consumed, with the net public health effect unknown.
Report
Share
Report
Share
Download to read offline
Recommended
Cannabis Science & Policy Summit - Day 1 - Smart
This document outlines a study examining the effects of growth in legal medical marijuana markets on substance use and abuse. It describes collecting new data on registered medical marijuana patients to measure the size of legal markets over time. Variation in state supply regulations and federal enforcement are used to identify how legal market size impacts recreational marijuana use and other health outcomes like traffic accidents and mortality. Results suggest that while medical marijuana laws alone have little effect, growth in the size of the legal market increases adolescent marijuana use but reduces alcohol- and opioid-related deaths among older adults by substituting marijuana for those substances.
Cannabis Science & Policy Summit - Day 1 - Sabet
This document discusses alternatives to legalizing marijuana that were presented in a RAND report on Vermont. It notes that most of the options presented in the RAND report were still versions of legalization, and that there are other models that do not involve legalizing marijuana. These include civil citation programs that require drug assessment, community service, and interventions for first-time offenders, diversion programs requiring drug education or treatment, and decriminalization laws requiring drug education or treatment following an offense. The document provides examples of such programs in Florida, New Jersey, Maryland, and Maryland's decriminalization law.
Cannabis Science & Policy Summit - Day 1 - Kagan
This document discusses options for regulating recreational marijuana in California if legalized. It recommends taking a relatively tight initial regulatory approach to create a single market, building in the ability to change regulations over time based on data, and requiring extensive data collection. Key regulatory areas to focus on include cultivation and production licensing, restricting sales to adults, establishing taxes, preventing impaired driving and abuse, and designating an oversight agency. An effective regulatory system would manage the entire supply chain, limit youth access, raise revenue, and monitor public health and safety impacts ongoing.
Cannabis Science & Policy Summit - Day 1 - Peyraube
Uruguay has reformed its drug policy based on a framework of security, public health, and human rights. It prioritizes human rights conventions and national sovereignty over international drug conventions. Uruguay regulates cannabis to reduce the negative impacts of drugs and incarceration for possession. The regulation creates a domestic cannabis industry and allows medical use and research. Adults can access cannabis through self-cultivation, cannabis clubs, or purchasing up to 40 grams per month from pharmacies. Production is licensed and regulated by the government.
Cannabis Science & Policy Summit - Day 1 - Midgette
This document summarizes a report on marijuana legalization in Vermont. It finds that marijuana use is more prevalent in Vermont than the rest of the US. Currently, Vermont spends $800,000-$1.1 million annually prohibiting marijuana. The report discusses 12 policy alternatives to the status quo and models potential tax revenue from legalization, finding it could be in the tens of millions annually from Vermont users alone. However, regulation costs and uncertainty around impacts on substance use make projections difficult.
Cannabis Science & Policy Summit - Day 2 - Orens
This document summarizes outcomes from the legalization of marijuana in Colorado over two years. Key findings include an increase in past month marijuana use prevalence and demand, with casual users accounting for more use. Prices have decreased while concentrate sales have risen. Legalization has had a strong positive economic impact, creating thousands of jobs and over $1 billion in revenue. The regulated market now serves nearly three-quarters of total marijuana demand in Colorado.
Cannabis Science & Policy Summit - Day 1 - Cruz
This document summarizes research on cannabis legalization in Uruguay. It discusses four areas of focus: public opinion analysis, impact on frequent consumers, cannabis clubs, and retail distribution. The presentation specifically discusses national surveys showing most Uruguayans initially disagreed with legalization but viewed medical cannabis and state intervention favorably, though many felt use had increased. However, data on use was inconsistent. Implementation of the cannabis law faces challenges of general disapproval, concerns over pharmacy distribution, and needs better communication and prevention strategies.
Cannabis Science & Policy Summit - Day 1 - Caulkins
This document discusses different aspects of legalizing marijuana, including defining levels of legalization and comparing marijuana legalization to other regulated substances and markets. It also provides statistics on current marijuana use patterns in the US, highlighting that most use is concentrated among relatively heavy users and those with substance abuse problems. The potential public health impacts of legalization are uncertain and will depend on how regulations shape the legal market.
Recommended
Cannabis Science & Policy Summit - Day 1 - Smart
This document outlines a study examining the effects of growth in legal medical marijuana markets on substance use and abuse. It describes collecting new data on registered medical marijuana patients to measure the size of legal markets over time. Variation in state supply regulations and federal enforcement are used to identify how legal market size impacts recreational marijuana use and other health outcomes like traffic accidents and mortality. Results suggest that while medical marijuana laws alone have little effect, growth in the size of the legal market increases adolescent marijuana use but reduces alcohol- and opioid-related deaths among older adults by substituting marijuana for those substances.
Cannabis Science & Policy Summit - Day 1 - Sabet
This document discusses alternatives to legalizing marijuana that were presented in a RAND report on Vermont. It notes that most of the options presented in the RAND report were still versions of legalization, and that there are other models that do not involve legalizing marijuana. These include civil citation programs that require drug assessment, community service, and interventions for first-time offenders, diversion programs requiring drug education or treatment, and decriminalization laws requiring drug education or treatment following an offense. The document provides examples of such programs in Florida, New Jersey, Maryland, and Maryland's decriminalization law.
Cannabis Science & Policy Summit - Day 1 - Kagan
This document discusses options for regulating recreational marijuana in California if legalized. It recommends taking a relatively tight initial regulatory approach to create a single market, building in the ability to change regulations over time based on data, and requiring extensive data collection. Key regulatory areas to focus on include cultivation and production licensing, restricting sales to adults, establishing taxes, preventing impaired driving and abuse, and designating an oversight agency. An effective regulatory system would manage the entire supply chain, limit youth access, raise revenue, and monitor public health and safety impacts ongoing.
Cannabis Science & Policy Summit - Day 1 - Peyraube
Uruguay has reformed its drug policy based on a framework of security, public health, and human rights. It prioritizes human rights conventions and national sovereignty over international drug conventions. Uruguay regulates cannabis to reduce the negative impacts of drugs and incarceration for possession. The regulation creates a domestic cannabis industry and allows medical use and research. Adults can access cannabis through self-cultivation, cannabis clubs, or purchasing up to 40 grams per month from pharmacies. Production is licensed and regulated by the government.
Cannabis Science & Policy Summit - Day 1 - Midgette
This document summarizes a report on marijuana legalization in Vermont. It finds that marijuana use is more prevalent in Vermont than the rest of the US. Currently, Vermont spends $800,000-$1.1 million annually prohibiting marijuana. The report discusses 12 policy alternatives to the status quo and models potential tax revenue from legalization, finding it could be in the tens of millions annually from Vermont users alone. However, regulation costs and uncertainty around impacts on substance use make projections difficult.
Cannabis Science & Policy Summit - Day 2 - Orens
This document summarizes outcomes from the legalization of marijuana in Colorado over two years. Key findings include an increase in past month marijuana use prevalence and demand, with casual users accounting for more use. Prices have decreased while concentrate sales have risen. Legalization has had a strong positive economic impact, creating thousands of jobs and over $1 billion in revenue. The regulated market now serves nearly three-quarters of total marijuana demand in Colorado.
Cannabis Science & Policy Summit - Day 1 - Cruz
This document summarizes research on cannabis legalization in Uruguay. It discusses four areas of focus: public opinion analysis, impact on frequent consumers, cannabis clubs, and retail distribution. The presentation specifically discusses national surveys showing most Uruguayans initially disagreed with legalization but viewed medical cannabis and state intervention favorably, though many felt use had increased. However, data on use was inconsistent. Implementation of the cannabis law faces challenges of general disapproval, concerns over pharmacy distribution, and needs better communication and prevention strategies.
Cannabis Science & Policy Summit - Day 1 - Caulkins
This document discusses different aspects of legalizing marijuana, including defining levels of legalization and comparing marijuana legalization to other regulated substances and markets. It also provides statistics on current marijuana use patterns in the US, highlighting that most use is concentrated among relatively heavy users and those with substance abuse problems. The potential public health impacts of legalization are uncertain and will depend on how regulations shape the legal market.
Cannabis Science & Policy Summit - Day 1 - Fortin
1) The document analyzes cannabis policy and markets in Colorado following legalization of recreational cannabis.
2) It finds evidence that the recreational market is cannibalizing the medical market, especially in tourist counties, but is also expanding overall demand.
3) A dual pricing scheme, with lower prices for medical patients and higher prices for recreational users, has successfully achieved price discrimination and appears optimal for balancing economic and social outcomes.
Cannabis Science & Policy Summit - Day 2 - Novak
This document summarizes a study that used latent class analysis to identify patterns of medical cannabis consumption among 50 patients in San Francisco. The analysis identified 4 classes: pure therapy (10%), pure euphoria (10%), mixed motives (55%), and smoked euphoria (25%). Characteristics like gender, medical conditions, and socioeconomic status were associated with class membership. Probability of consumption varied by day of week and payday cycles, with higher use on weekends and paydays. The findings suggest medical cannabis is used more for euphoria than purely medical reasons for most patients.
Cannabis Science & Policy Summit - Day 1 - Hall
This document discusses complications that arise when comparing the risks of alcohol and cannabis. While cannabis appears less harmful than alcohol in some ways, its legal status and patterns of use are confounded by prohibition. Additionally, risks may increase with legalization, such as from more potent products, and cannabis use has been correlated with poorer cognitive and social outcomes from sustained daily use. Finally, there are regulatory and health education challenges to legalizing cannabis in a way that minimizes risks of dependence and impairment while developing credible public health advice.
Cannabis Science & Policy Summit - Day 1 - Courtwright
The document discusses regulating cannabis as a "temptation good" by learning from other vices like alcohol and proposes a "Goth-Pot" system where cannabis would be produced and sold by a public monopoly trust with limited advertising, retail locations, and product potency to prevent abuse and unwanted habits, similar to Sweden's historical Gothenburg System for regulating alcohol. It also includes poll data showing most Americans see tobacco as more harmful than alcohol, sugar, or marijuana.
Cannabis Science & Policy Summit - Day 1 - Wetterau
1. ASAM supports decriminalizing marijuana possession for personal use and treating it as a civil offense linked to contingencies like mandated clinical assessment and treatment.
2. ASAM does not support legalizing marijuana and recommends caution in jurisdictions that have not legalized it yet until more is learned from places that have.
3. The document outlines several recommendations from ASAM for regulating legalized recreational marijuana and expanding access to treatment and prevention services for marijuana use, especially among youth.
Legal Marijuana Industry
This PowerPoint was prepared for a Management 402 class. The assignment was to take an infant industry and propose possible strategies for profit potential. So, this presentation explores the legal marijuana industry and the profit potential that is waiting to be gained.
Marijuana Legalization Policy Analysis
This document analyzes the policy of decriminalizing recreational marijuana in the United States. It outlines the goals of decriminalization, which include treating marijuana similarly to alcohol and tobacco to reduce the burden of anti-cannabis laws. It notes over 750,000 marijuana arrests in 2012, costing $7.5-10 billion annually. Advantages include generating $8.7 billion in annual tax revenue and freeing law enforcement resources. Disadvantages include potential health risks and easier youth access. Overall the document argues the benefits of legalization outweigh the costs.
Cannabis Science & Policy Summit - Day 1 - Seiveright
Jamaica has recently passed legislation decriminalizing possession of small amounts of cannabis and legalizing its medical use. This represents progress toward reforming cannabis laws, which were made stricter under British rule and international treaties, despite cannabis having traditional medical and religious uses in Jamaica. The new law allows possession of up to 2 ounces, cultivation of up to 5 plants per household, and imports/exports for medical or scientific purposes. However, regulations are still pending and challenges remain regarding banking restrictions and reactions from other countries.
State Efforts to Rein in Drug Costs
This document summarizes state legislative efforts to address rising prescription drug prices. It finds that in 2018, 28 states passed 45 new laws focused on drug costs, particularly related to pharmacy benefit managers and increasing transparency. It also discusses emerging policy approaches like price gouging laws, drug affordability boards empowered to set rates, and importation from Canada. The document predicts more state action on these issues in 2019 and provides resources for advocates and legislators working on drug pricing reforms.
How is drug spending affected in the year 2017
As per the reports published in American Journal of Health-System Pharmacy (AJHP) in the year 2016, national trends in prescription drug expenditures were projected to increase by 6 to 8% in 2017 across all healthcare settings.
Crime and Policy III: Partnership for Safe Medicines overview for 2021
Crime and Policy III: Partnership for Safe Medicines overview for 2021The Partnership For Safe Medicines
What have been the major crimes and policy developments in the space of counterfeit medicines? PSM reviews major prosecutions and legislation from the first half of 2021.Family advocate webinar 2/2/2022
PSM presented a special webinar for families affected by counterfeits and fentanyl. Learn about opportunities to make your voice heard. You can watch the presentation at https://youtu.be/FmBv3Bb7ZHI
The legalization of marijuana
This document discusses arguments for and against legalizing marijuana. It provides statistics showing that marijuana has never caused a death, while other legal and illegal drugs cause thousands of deaths each year. It notes that marijuana is currently legalized in 16 states and Washington D.C. The document explores some pros of legalization, such as reduced harmfulness compared to other drugs, individual freedom, and potential tax revenues. It also briefly mentions some cons, such as potential negative health impacts, before concluding by acknowledging both sides of the debate.
Magellan Strategies EPA Regulation Survey Press Release 061214
Magellan Strategies conducted surveys in 8 battleground states to measure voter opinion on the EPA's newly proposed carbon emission regulations. The key findings show that on average, 37.3% of voters support the regulation, 47.1% oppose it, and 15.6% have no opinion. Additionally, 55.2% of respondents are more likely to oppose Senate candidates that support the regulation. When given further information on economic impacts, opposition increases to over 59%. The surveys conclude that any candidate supporting the regulation will face risks in these 2014 elections.
Canberra Drug Law Reform Apgdlr 2006
The document discusses the current status and future prospects of drug law reform. It summarizes that the global drug situation continues to worsen, with more countries, drug quantities, and adverse consequences. There is growing support for harm reduction policies and programs over prohibitionist approaches. However, progress requires pragmatic approaches that are both economically and politically sustainable, through compromise instead of attempting to eradicate drug use entirely. Reform will likely be a slow evolution rather than a rapid revolution.
Magellan Strategies NMA EPA Regulation Survey Summary 061114
Survey of likely 2014 likely voters in Arkansas, Colorado, Georgia, Kentucky, Louisiana, Michigan, Montana and North Carolina measuring opinion of the proposed EPA carbon emissions regulations.
Public Opinion On Prescription Drugs And Their Prices
- According to polls from 2015-2019, around 6 in 10 Americans currently take at least one prescription medication and 1 in 4 take 4 or more. While most say the cost of prescription drugs is unreasonable, around 3 in 4 currently taking medications say affording them is easy. However, those taking more medications report more cost problems.
- Around 3 in 10 Americans have not taken their medication as prescribed at some point due to costs, such as not filling a prescription, cutting pills in half, or taking over-the-counter drugs instead.
- Majorities of the public favor policies to lower drug costs like requiring list prices in ads, easier generics, and government negotiations. However, views on the best approach vary by
Consequences of Medical Marijuana legalization
The document discusses the consequences of legalizing medical marijuana. It outlines symptoms of marijuana use like rapid heart rate and memory loss. It also discusses potential health risks like cancer and addiction. However, it also reviews marijuana's medical properties in relieving pain, seizures, and other conditions. Studies from countries that have legalized marijuana, like Holland and Portugal, found crime and drug use did not significantly increase and in some cases decreased. The document aims to provide information to help decide whether to legalize medical marijuana.
Consumo Mundial de Drogas.
The document summarizes key findings from the UNODC's World Drug Report 2016. It finds that while the number of women arrested for drug offenses has increased, the proportion of women in drug cases has decreased. It also discusses trends in drug production, use, and related health issues. Additionally, it examines the relationship between development levels, socioeconomic status, and drug use. The report concludes that development initiatives and responses to drug problems must work in tandem to be effective and minimize unintended impacts. Drug policies should be evidence-based, sensitive to vulnerable groups, and aim to reduce stigma and imprisonment for minor drug offenses.
Alcohol and drugs in relation to crime
Substance abuse has risen 68% in the last 10 years and is linked to crimes like anti-social behavior and violence. Studies show that 70% of offenders abused alcohol in the past and 50% still have issues with it. Age 16-24 year old males are most likely to abuse substances and commit crimes. Poverty and lack of education are also linked to higher rates of substance abuse and crime, as those suffering from social exclusion may turn to drugs or alcohol to cope or see dealing as their only means. Finally, regular cannabis use increases the risk of mental illness, which is in turn linked to criminal behavior.
Cannabis Science & Policy Summit - Day 1 - Williams
The document summarizes state medical marijuana programs in the United States. It finds that there is great variation among state programs, with an average score of 1.96 out of 7 on factors reflecting a medical model. Programs enacted more recently through state legislatures in Northeastern and Midwestern states (medicalized programs) tend to be more highly regulated compared to earlier voter initiative programs in Western states (non-medical programs). Medicalized programs have fewer participants, with an average of 58 enrollments per 100,000 residents compared to over 1,000 in non-medical programs. The presentation concludes with a case study of New York's strictly regulated medical marijuana program.
Cannabis Science & Policy Summit - Day 2 - Jacobson
This document discusses the future of medical cannabis. It outlines a spectrum of cannabis use from medical to therapeutic/wellness to recreational. While some conditions like cancer pain, nausea, and epilepsy have seen medical cannabis legalized, mainstream medicine does not recognize it as a legitimate treatment due to a lack of chemical definition and clinical research. More research is needed to establish safe and effective dosing as well as drug interactions before medical cannabis can be fully accepted. The current system also fails patients in terms of accessibility, insurance coverage, and appropriate medical supervision.
More Related Content
What's hot
Cannabis Science & Policy Summit - Day 1 - Fortin
1) The document analyzes cannabis policy and markets in Colorado following legalization of recreational cannabis.
2) It finds evidence that the recreational market is cannibalizing the medical market, especially in tourist counties, but is also expanding overall demand.
3) A dual pricing scheme, with lower prices for medical patients and higher prices for recreational users, has successfully achieved price discrimination and appears optimal for balancing economic and social outcomes.
Cannabis Science & Policy Summit - Day 2 - Novak
This document summarizes a study that used latent class analysis to identify patterns of medical cannabis consumption among 50 patients in San Francisco. The analysis identified 4 classes: pure therapy (10%), pure euphoria (10%), mixed motives (55%), and smoked euphoria (25%). Characteristics like gender, medical conditions, and socioeconomic status were associated with class membership. Probability of consumption varied by day of week and payday cycles, with higher use on weekends and paydays. The findings suggest medical cannabis is used more for euphoria than purely medical reasons for most patients.
Cannabis Science & Policy Summit - Day 1 - Hall
This document discusses complications that arise when comparing the risks of alcohol and cannabis. While cannabis appears less harmful than alcohol in some ways, its legal status and patterns of use are confounded by prohibition. Additionally, risks may increase with legalization, such as from more potent products, and cannabis use has been correlated with poorer cognitive and social outcomes from sustained daily use. Finally, there are regulatory and health education challenges to legalizing cannabis in a way that minimizes risks of dependence and impairment while developing credible public health advice.
Cannabis Science & Policy Summit - Day 1 - Courtwright
The document discusses regulating cannabis as a "temptation good" by learning from other vices like alcohol and proposes a "Goth-Pot" system where cannabis would be produced and sold by a public monopoly trust with limited advertising, retail locations, and product potency to prevent abuse and unwanted habits, similar to Sweden's historical Gothenburg System for regulating alcohol. It also includes poll data showing most Americans see tobacco as more harmful than alcohol, sugar, or marijuana.
Cannabis Science & Policy Summit - Day 1 - Wetterau
1. ASAM supports decriminalizing marijuana possession for personal use and treating it as a civil offense linked to contingencies like mandated clinical assessment and treatment.
2. ASAM does not support legalizing marijuana and recommends caution in jurisdictions that have not legalized it yet until more is learned from places that have.
3. The document outlines several recommendations from ASAM for regulating legalized recreational marijuana and expanding access to treatment and prevention services for marijuana use, especially among youth.
Legal Marijuana Industry
This PowerPoint was prepared for a Management 402 class. The assignment was to take an infant industry and propose possible strategies for profit potential. So, this presentation explores the legal marijuana industry and the profit potential that is waiting to be gained.
Marijuana Legalization Policy Analysis
This document analyzes the policy of decriminalizing recreational marijuana in the United States. It outlines the goals of decriminalization, which include treating marijuana similarly to alcohol and tobacco to reduce the burden of anti-cannabis laws. It notes over 750,000 marijuana arrests in 2012, costing $7.5-10 billion annually. Advantages include generating $8.7 billion in annual tax revenue and freeing law enforcement resources. Disadvantages include potential health risks and easier youth access. Overall the document argues the benefits of legalization outweigh the costs.
Cannabis Science & Policy Summit - Day 1 - Seiveright
Jamaica has recently passed legislation decriminalizing possession of small amounts of cannabis and legalizing its medical use. This represents progress toward reforming cannabis laws, which were made stricter under British rule and international treaties, despite cannabis having traditional medical and religious uses in Jamaica. The new law allows possession of up to 2 ounces, cultivation of up to 5 plants per household, and imports/exports for medical or scientific purposes. However, regulations are still pending and challenges remain regarding banking restrictions and reactions from other countries.
State Efforts to Rein in Drug Costs
This document summarizes state legislative efforts to address rising prescription drug prices. It finds that in 2018, 28 states passed 45 new laws focused on drug costs, particularly related to pharmacy benefit managers and increasing transparency. It also discusses emerging policy approaches like price gouging laws, drug affordability boards empowered to set rates, and importation from Canada. The document predicts more state action on these issues in 2019 and provides resources for advocates and legislators working on drug pricing reforms.
How is drug spending affected in the year 2017
As per the reports published in American Journal of Health-System Pharmacy (AJHP) in the year 2016, national trends in prescription drug expenditures were projected to increase by 6 to 8% in 2017 across all healthcare settings.
Crime and Policy III: Partnership for Safe Medicines overview for 2021
Crime and Policy III: Partnership for Safe Medicines overview for 2021The Partnership For Safe Medicines
What have been the major crimes and policy developments in the space of counterfeit medicines? PSM reviews major prosecutions and legislation from the first half of 2021.Family advocate webinar 2/2/2022
PSM presented a special webinar for families affected by counterfeits and fentanyl. Learn about opportunities to make your voice heard. You can watch the presentation at https://youtu.be/FmBv3Bb7ZHI
The legalization of marijuana
This document discusses arguments for and against legalizing marijuana. It provides statistics showing that marijuana has never caused a death, while other legal and illegal drugs cause thousands of deaths each year. It notes that marijuana is currently legalized in 16 states and Washington D.C. The document explores some pros of legalization, such as reduced harmfulness compared to other drugs, individual freedom, and potential tax revenues. It also briefly mentions some cons, such as potential negative health impacts, before concluding by acknowledging both sides of the debate.
Magellan Strategies EPA Regulation Survey Press Release 061214
Magellan Strategies conducted surveys in 8 battleground states to measure voter opinion on the EPA's newly proposed carbon emission regulations. The key findings show that on average, 37.3% of voters support the regulation, 47.1% oppose it, and 15.6% have no opinion. Additionally, 55.2% of respondents are more likely to oppose Senate candidates that support the regulation. When given further information on economic impacts, opposition increases to over 59%. The surveys conclude that any candidate supporting the regulation will face risks in these 2014 elections.
Canberra Drug Law Reform Apgdlr 2006
The document discusses the current status and future prospects of drug law reform. It summarizes that the global drug situation continues to worsen, with more countries, drug quantities, and adverse consequences. There is growing support for harm reduction policies and programs over prohibitionist approaches. However, progress requires pragmatic approaches that are both economically and politically sustainable, through compromise instead of attempting to eradicate drug use entirely. Reform will likely be a slow evolution rather than a rapid revolution.
Magellan Strategies NMA EPA Regulation Survey Summary 061114
Survey of likely 2014 likely voters in Arkansas, Colorado, Georgia, Kentucky, Louisiana, Michigan, Montana and North Carolina measuring opinion of the proposed EPA carbon emissions regulations.
Public Opinion On Prescription Drugs And Their Prices
- According to polls from 2015-2019, around 6 in 10 Americans currently take at least one prescription medication and 1 in 4 take 4 or more. While most say the cost of prescription drugs is unreasonable, around 3 in 4 currently taking medications say affording them is easy. However, those taking more medications report more cost problems.
- Around 3 in 10 Americans have not taken their medication as prescribed at some point due to costs, such as not filling a prescription, cutting pills in half, or taking over-the-counter drugs instead.
- Majorities of the public favor policies to lower drug costs like requiring list prices in ads, easier generics, and government negotiations. However, views on the best approach vary by
Consequences of Medical Marijuana legalization
The document discusses the consequences of legalizing medical marijuana. It outlines symptoms of marijuana use like rapid heart rate and memory loss. It also discusses potential health risks like cancer and addiction. However, it also reviews marijuana's medical properties in relieving pain, seizures, and other conditions. Studies from countries that have legalized marijuana, like Holland and Portugal, found crime and drug use did not significantly increase and in some cases decreased. The document aims to provide information to help decide whether to legalize medical marijuana.
Consumo Mundial de Drogas.
The document summarizes key findings from the UNODC's World Drug Report 2016. It finds that while the number of women arrested for drug offenses has increased, the proportion of women in drug cases has decreased. It also discusses trends in drug production, use, and related health issues. Additionally, it examines the relationship between development levels, socioeconomic status, and drug use. The report concludes that development initiatives and responses to drug problems must work in tandem to be effective and minimize unintended impacts. Drug policies should be evidence-based, sensitive to vulnerable groups, and aim to reduce stigma and imprisonment for minor drug offenses.
Alcohol and drugs in relation to crime
Substance abuse has risen 68% in the last 10 years and is linked to crimes like anti-social behavior and violence. Studies show that 70% of offenders abused alcohol in the past and 50% still have issues with it. Age 16-24 year old males are most likely to abuse substances and commit crimes. Poverty and lack of education are also linked to higher rates of substance abuse and crime, as those suffering from social exclusion may turn to drugs or alcohol to cope or see dealing as their only means. Finally, regular cannabis use increases the risk of mental illness, which is in turn linked to criminal behavior.
What's hot (20)
Cannabis Science & Policy Summit - Day 1 - Courtwright
Cannabis Science & Policy Summit - Day 1 - Courtwright
Cannabis Science & Policy Summit - Day 1 - Wetterau
Cannabis Science & Policy Summit - Day 1 - Wetterau
Cannabis Science & Policy Summit - Day 1 - Seiveright
Cannabis Science & Policy Summit - Day 1 - Seiveright
Crime and Policy III: Partnership for Safe Medicines overview for 2021
Crime and Policy III: Partnership for Safe Medicines overview for 2021
Magellan Strategies EPA Regulation Survey Press Release 061214
Magellan Strategies EPA Regulation Survey Press Release 061214
Magellan Strategies NMA EPA Regulation Survey Summary 061114
Magellan Strategies NMA EPA Regulation Survey Summary 061114
Public Opinion On Prescription Drugs And Their Prices
Public Opinion On Prescription Drugs And Their Prices
Viewers also liked
Cannabis Science & Policy Summit - Day 1 - Williams
The document summarizes state medical marijuana programs in the United States. It finds that there is great variation among state programs, with an average score of 1.96 out of 7 on factors reflecting a medical model. Programs enacted more recently through state legislatures in Northeastern and Midwestern states (medicalized programs) tend to be more highly regulated compared to earlier voter initiative programs in Western states (non-medical programs). Medicalized programs have fewer participants, with an average of 58 enrollments per 100,000 residents compared to over 1,000 in non-medical programs. The presentation concludes with a case study of New York's strictly regulated medical marijuana program.
Cannabis Science & Policy Summit - Day 2 - Jacobson
This document discusses the future of medical cannabis. It outlines a spectrum of cannabis use from medical to therapeutic/wellness to recreational. While some conditions like cancer pain, nausea, and epilepsy have seen medical cannabis legalized, mainstream medicine does not recognize it as a legitimate treatment due to a lack of chemical definition and clinical research. More research is needed to establish safe and effective dosing as well as drug interactions before medical cannabis can be fully accepted. The current system also fails patients in terms of accessibility, insurance coverage, and appropriate medical supervision.
Cannabis Science & Policy Summit - Day 1 - Jelsma
This document discusses cannabis regulation and the UN drug control treaties. It notes that the 1961 Single Convention placed cannabis in Schedule I and IV, requiring abolition of traditional and medical uses. However, some countries were allowed transitional reservations for traditional use. The document questions whether the WHO ever properly reviewed cannabis or recommended its scheduling. It discusses options for reforming the UN drug treaties to allow more flexibility for countries to design their own cannabis policies.
Cannabis Science & Policy Summit - Day 1 - Rolles
The document outlines 10 steps for designing legal access to cannabis: 1) agree on policy aims and principles; 2) establish a methodology to evaluate policy impacts; 3) establish an independent commission of experts to develop policy details; 4) identify and mitigate key risks learned from regulating alcohol and tobacco; 5) ensure enforcement structures and capacity for any new regulatory framework. The steps also include controlling commercial incentives to increase consumption; initially meeting existing demand through legal supply roughly matching illegal supply; avoiding diversifying cannabis products and prohibiting advertising as much as possible; and balancing market access and appeal.
Cannabis Science & Policy Summit - Day 1 - Mead
This document discusses GW Pharmaceuticals' investigation of Cannabidiol (CBD) as a potential therapeutic product. GW Pharmaceuticals is developing a purified CBD product called Epidiolex to treat rare and severe forms of childhood epilepsy. Clinical trials showed Epidiolex significantly reduced seizures in patients with Dravet Syndrome. If approved by the FDA, Epidiolex would be the first prescription drug in the United States containing a purified drug substance derived from cannabis. The FDA approval process ensures patient safety and requires rigorous clinical trials, but takes years and is expensive.
Cannabis Science & Policy Summit - Day 2 - Hope
The document discusses issues related to cannabis policy in Mexico. It provides statistics on homicides, drug cases, eradication and seizures of marijuana from 2005-2015. It shows that 50% of homicides with firearms from 2007-2014 occurred in regions known for marijuana production. The document also shows data on the percentage of inmates in state penitentiaries that were incarcerated for drug retail sales (5%), crimes against health (7%) and other crimes (88%). It acknowledges that precisely estimating the effects of changing drug policy is impossible and that displacement effects are unknown. It concludes by thanking the audience and providing contact information for Alejandro Hope who presented the information.
Cannabis Science & Policy Summit - Day 2 - Flaster
The document summarizes a panel discussion on adulterants in cannabis regulation and testing, with panelists from various cannabis industry organizations. The panel discusses issues around growing practices, ensuring quality and consistency of cannabis products, and the importance of testing for contaminants and validating test methods to verify constituents and ensure consumer safety. Proper growing, accountability through testing, and transparency were emphasized as important to building trust in the cannabis industry.
Cannabis Science & Policy Summit - Day 2 - Reuter
1) Canada is taking a sensible approach to legalizing cannabis by planning in advance, articulating specific goals, developing an evaluation process, and coordinating federal and provincial governments.
2) A report from CAMH advocates for a government monopoly over supply to allow for adjustments to product mix as understanding of harms increases, and argues this approach promotes health equity by reducing arrests of minorities and poor people under prohibition.
3) However, the report is criticized for not adequately recognizing potential benefits of cannabis use or considering whether pleasure should count in policymaking, and relying too much on a health model without considering other social harms.
Cannabis Science & Policy Summit - Day 2 - de Kort
The document summarizes the origins and development of Dutch cannabis policy from the 1970s to the present. Key events included the recommendations of committees in the late 1960s and early 1970s to decriminalize cannabis, the introduction of heroin in 1972 which led to stricter drug laws, and the rise of coffee shops in the 1970s-1980s which established a system of toleration for soft drugs like cannabis. The coffee shop system developed pragmatically rather than through a formal policy and expectations of legalization were not met. Over time coffee shops faced some regulation to address issues like advertising, hard drugs, nuisances, and minors.
Cannabis Science & Policy Summit - Day 2 - Sterling
The document summarizes Maryland's medical cannabis program, including:
1) The program was created in 2013 and is overseen by the Natalie M. LaPrade Medical Cannabis Commission. The statute and regulations govern growing, processing, dispensing and use of medical cannabis.
2) Strict security and safety measures are in place, including background checks, video surveillance, inventory tracking from "seed to sale", and limits on the number of growers and dispensaries.
3) The program is funded entirely through license fees, not taxpayer money. Licenses have been awarded for growing, processing and dispensing medical cannabis.
Cannabis Science & Policy Summit - Day 2 - Trautmann
The national cannabis policy in the Netherlands has swung like a pendulum since the 1990s, moving between more liberal and restrictive approaches. Originally, a more liberal policy developed in response to social changes and protests in the 1960s, allowing for regulated cannabis sales. However, international criticism and issues like drug tourism led to a more restrictive approach focused on supply reduction and public order from the 2000s onward. Stricter measures unintentionally increased street dealing and organized crime involvement. More recently, support has increased for a less restrictive approach, including some cities exploring regulated cannabis production. Current national policy still prohibits production but condones retail sales through "coffeeshops" under local regulations.
Cannabis Science & Policy Summit - Day 2 - Blickman
The document summarizes the debate around regulating the cannabis supply system in the Netherlands. It outlines that mayors, judges, and public opinion favor regulation over the current policy of tolerance. The mayors revolt argues that tolerance is bankrupt and increases crime, while judges are increasingly uneasy about contradictions in current policy. The document proposes regulating cultivation and supply to reduce crime and better protect public health.
Cannabis Science & Policy Summit - Day 2 - MacCoun
This document summarizes research on the Dutch approach to cannabis policy, known as "de facto legalization". Key points include:
- During the first decade after policy change in 1976, cannabis use prevalence did not increase, but sharply rose in the second decade due to commercialization of coffeeshops.
- The Dutch system maintains high cannabis prices through prohibition on growers/traffickers while allowing sale to users, unlike potential US legalization with aggressive marketing and minimal price controls.
- Experts note the Dutch policy was a product of addressing the heroin threat in the 1970s but the policy window has since closed, with unintended consequences like street dealing and production shifting elsewhere.
Cannabis Science & Police Summit - Day 1 - Zinsmeister
The document discusses public opinion and the UN drug conventions regarding drug policy reforms. It summarizes that legalization is still a minority position at the UN as the majority of member states still favor prohibitionist approaches. Several polls and surveys cited show that public opinion in Europe and Latin America also generally opposes marijuana legalization and favors maintaining prohibition. When asked about decriminalization, reaction is still mixed. The Latin American public sees drugs as both a security and public health issue.
Cannabis Science & Policy Summit - Day 1 - Miller
This document analyzes the legal marijuana market in Washington state using traceability data from the state's seed-to-sale tracking system. Three key findings are: (1) Prices fell substantially over time due to increased supply and competition among producers and processors; (2) While product characteristics changed dramatically, retail quantities were not significantly affected by a tax change, suggesting demand is inelastic; (3) Entry into the market was high initially but has slowed, and supply has increased substantially.
Viewers also liked (15)
Cannabis Science & Policy Summit - Day 1 - Williams
Cannabis Science & Policy Summit - Day 1 - Williams
Cannabis Science & Policy Summit - Day 2 - Jacobson
Cannabis Science & Policy Summit - Day 2 - Jacobson
Cannabis Science & Policy Summit - Day 2 - Flaster
Cannabis Science & Policy Summit - Day 2 - Flaster
Cannabis Science & Policy Summit - Day 2 - de Kort
Cannabis Science & Policy Summit - Day 2 - de Kort
Cannabis Science & Policy Summit - Day 2 - Sterling
Cannabis Science & Policy Summit - Day 2 - Sterling
Cannabis Science & Policy Summit - Day 2 - Trautmann
Cannabis Science & Policy Summit - Day 2 - Trautmann
Cannabis Science & Policy Summit - Day 2 - Blickman
Cannabis Science & Policy Summit - Day 2 - Blickman
Cannabis Science & Policy Summit - Day 2 - MacCoun
Cannabis Science & Policy Summit - Day 2 - MacCoun
Cannabis Science & Police Summit - Day 1 - Zinsmeister
Cannabis Science & Police Summit - Day 1 - Zinsmeister
Similar to Cannabis Science & Policy Summit - Day 1 - MacCoun
Lucas Shin - Sample Work
This document provides an overview and summary of legal issues affecting the tobacco industry in the United States. It discusses two main legal issues: 1) advertisements, focusing on the tobacco industry's defense of free speech rights under the First Amendment and tests for restricting commercial speech, and 2) liability, regarding questions of who is responsible for health costs caused by tobacco and debates around product liability. The document outlines relevant legislation and court cases on these issues and indicates they will be analyzed in relation to arguments from the tobacco industry and those harmed by tobacco.
Legalising marijuana
Colorado and Washington are experimenting with legalizing marijuana, challenging the international consensus of prohibiting drugs. This experiment may help determine if legalization increases drug use and undermine Mexican drug gangs. It also provides a model for regulating harder drugs. The US federal government plans to allow this experiment to move forward for now, despite being in breach of UN drug conventions, in hopes of reforming outdated drug policies.
Marijuna and Canada - All you need to know
Canada will enter a new era starting October 17, 2018 as pot marijuana will be legal in Canada.
The Liberals rushed the Marijuana/Pot Law as part of building up for the 2019 election. The Law is flawed
There is cost when it comes to marijuana legalization that is all but ignored by the Liberals, i.e. enforcement, Quality Control, mental health, addiction, healthcare cost, distribution, criminal code, etc.
Pot will open up an new business segment for the economy which will help economic growth. There have been issues with
Pot facilities in the past including environmental issues (i.e. air quality, chemicals, water management, etc)
Pot will not stop the black market of marijuana. The black market is already a big issue for other areas of the economy - https://www150.statcan.gc.ca/n1/daily-quotidien/181012/dq181012a-eng.htm. This would mean the need for more CRA auditors, Police Enforcement, etc. No where has the Liberal discussed what tools they will deploy to stem the underground economy.
Will COVID-19 Push Marijuana Legalization Forward or Slow It Down?
Will the coronavirus and after effects cause marijuana legalization to jump forward or fall back, read this https://cannabis.net/blog/opinion/will-covid19-push-back-or-move-up-cannabis-legalization-at-the-federal-and-state-level
Marijuana / Cannabis| Policy Review and Analysis| Canada| April 2019
Canada legalized pot but the legal, distribution, etc processes have been a failure.
There needs to be a fully costed model including allocation of moneys to mental health, law enforcement, licensing, product quality and other areas. The government should not be treating the marijuana as windfall unless it allocates funds to support all aspect of the program
The government has to open and transparent with the awarding licensing process from production to distribution/retail.
The government will need to work with government around to world to support changing the laws for marijuana
Foreign Aid will need to be review in terms of law enforcement to countries like Mexico, Colombia, Haiti, etc.
Age limits will need to be set, i.e. 19
Liberals have failed on marijuana, especially as the illegal market continues to exist.
Black market and Pot will never disappear - https://www.bnnbloomberg.ca/cannabis-canada-daily-black-market-accounts-for-nearly-80-of-pot-spending-1.1222534
2019 Election| Legalization of Cannabis (Pot) | Canada | July 2019
Passing a bill and having full efficient supply chain for cannabis are two different issues
Feds push the cannabis law before law enforcement and the provinces were ready to handle the legalization of pot
Annual retail sales market for marijuana is running about $1B. The GST from the sales is estimated to be about $70M / year https://www150.statcan.gc.ca/n1/daily-quotidien/190621/dq190621a-eng.htm
Healthcare only recently finalized process and sale of edibles - https://www.canada.ca/en/health-canada/news/2019/06/health-canada-finalizes-regulations-for-the-production-and-sale-of-edible-cannabis-cannabis-extracts-and-cannabis-topicals.html
Liberals rushed out the legalization of pot as way to get a win when they are failing as a govt - https://www.slideshare.net/paulyoungcga/justin-trudeau-and-liberals-success-or-failure
Marijuana Industry| Canada| February 2019
This presentation discusses Canada legalizing marijuana in October 2018. It covers short and long term health effects, the UN's stance, worldwide enforcement efforts, and the potential costs and tax revenue for the government. The medical marijuana industry may be impacted as legalization could lower prices. The recreational market is estimated to be $5-8.7 billion annually. Ontario will sell marijuana online through the Ontario Cannabis Store and eventually through private retail stores starting in 2019. Canopy Growth Corp is a major producer that could benefit from legalization.
Legalization of Marijuana - Canada - August 2018
The document discusses Canada legalizing marijuana in October 2018 and analyzes the economic and health effects. It outlines the agenda which includes what marijuana is, short and long term side effects, the UN and world views, implementation costs, the medical and recreational marijuana markets and industries, and one of the major companies in the field, Canopy Growth Corp. It provides details on taxation plans and the potential market size in Canada.
The Futility of the War on Drugs in 2020
Why the War on Drugs is over, read this https://cannabis.net/blog/opinion/the-futility-of-the-war-on-drugs-in-2020
Marijuana Policy| Canada| January 2019
Canada legalized marijuana in October 2018. This presentation discusses the economic and health effects of legalization. It outlines short and long term side effects, the UN and world views on marijuana, and costs of implementing legalization. It also examines the potential size of the Canadian marijuana market, medical marijuana industry impacts, pricing statistics, Ontario's plan for private retail stores, and the major player Canopy Growth Corp. Legalization may generate billions annually but also incur upfront and ongoing costs for additional social programs and regulations.
Drug Policy Reform: 2013 in progress 2013-01-29
A brief presentation of the major trends and events in the Drug Policy Debate in 2013. Latin America is taking the lead with Colombia setting up an Advisory Commission on Drug Policy, Uruguay launching a national debate on marijuana legalization, and Guatemala taking the lead of the global drug policy debate.
Meanwhile, the US Federal Government seems to take an hands-off approach to marijuana legalization while more states are lining up to legalize medical or recreation use.
Canada Cannabis Policy: Assessment and Commentary
This presentation will discuss both the economic as well as side effects to legalizing marijuana in Canada.
Government policies for Legalizing Marijuana - Canada - Analysis and Commentary
This presentation discusses the effort by the Government of Canada to legalised Pot/Marijuana in Canada.
The presentation will look at all aspects of legalising marijuana including costs associated to the program as well as the revenue that could be generated from pot/marijuana sales.
Policy| Cannabis| Canada | April 2019
This presentation will discuss both the economic as well as side effects to legalizing marijuana in Canada.
Government policies - Marijuana - Canada - analysis and commentary - july 2017
This document discusses Canada's potential policy to legalize marijuana. It outlines the agenda which includes discussing what marijuana is, potential short-term and long-term health effects, international drug policies, estimates for the potential marijuana market size in Canada, and considerations for the medical marijuana industry and key players like Canopy Growth Corp. The document emphasizes that legalizing marijuana will require costs to support new regulatory programs and that the government needs a fully costed model to avoid treating marijuana tax revenue as a windfall.
Canada| Policy Analysis| Cannabis
This document provides an overview and agenda for a presentation on the legalization of marijuana in Canada. It discusses what marijuana is, potential short-term and long-term side effects, the UN's view, worldwide enforcement efforts, the costs of implementing legalization in Canada, the medical and recreational marijuana markets, pricing outlooks, and key companies in the industry like Canopy Growth. It also covers Canada's plans to legalize marijuana by October 2018 and how this may impact relations with the United States.
Policy Review| Cannabis (Marijuana)| Canada| July 2021
This document provides an overview and analysis of Canada's legalization of marijuana. It begins with biographical information about the author, Paul Young, and his credentials. The bulk of the document is a slide presentation outlining key points about Canada's legalization of marijuana, including what marijuana is, potential health effects, the UN's view, estimates of the size of the legal marijuana market in Canada, impacts on the existing medical marijuana industry, pricing information, Ontario's plans to transition to private retail stores, and considerations around taxation and regulation. Overall, the document analyzes both the economic opportunities and public health challenges associated with Canada legalizing recreational marijuana use.
John Barrymore Feb. 24, 2015BA 3103 –XXXT&R.docx
John Barrymore Feb. 24, 2015
BA 3103 –XXX
T&R, 11:00 AM – 12:20 PM
Big Tobacco and the Advent of E-Cigarettes
Background
The U.S. tobacco industry is among the most heavily regulated and heavily taxed industries in the United States (The Economist, 2014). Medical evidence of the adverse effects of smoking continues to grow, and the share of American adults who smoke has declined markedly during the past fifty years, from 42% in 1965 to less than 18% in 2013 (CDC, 2013). But in spite of ever-increasing regulation and public wariness of the U.S. tobacco industry, tobacco companies continue to thrive. This oligopoly industry, dominated by big tobacco companies Altria, Reynolds American, and Lorillard, serves a shrinking but remarkably loyal customer base. Critics are quick to point out that, despite extensive regulation of the marketing practices in the industry, tobacco products remain highly lucrative, with sales of over $66 billion in 2014 (Hargreaves, 2014).
This beleaguered but very profitable industry must now deal with another, potentially very disruptive innovation in the form of e-cigarettes. This new product category, the modern version of which dates from 2007, generated U.S. sales of $2.5 billion in 2014 (Richtel, 2014). Although the e-cigarette sector is still relatively small, it clearly has the potential to disrupt tobacco sales in the coming years. E-cig use is generally perceived to be less unhealthful than cigarette smoking, and the e-cig habit is substantially less costly than consuming tobacco cigarettes (Richtel, 2014). Moreover, e-cigarettes are far less regulated than tobacco products, without many of the marketing constraints.
The early success of e-cigarettes has not gone unnoticed by the big tobacco companies. Lorillard was the first to enter this sector with the acquisition in 2012 of the Blu eCig brand (Esterl, 2012). Since then, Altria and Reynolds American have indicated their intention to introduce e-cig product lines (Richtel, 2014).
Problem Statement
Tobacco companies must address the advent of e-cigarettes in order to defend their tobacco business and to identify business opportunities in the growing e-cigarette product sector.
Alternative
Solution
s
In order to limit the impact of e-cigarettes on the sales of tobacco cigarettes, tobacco companies can lobby for additional regulation of this new product category. Increased regulation will help to “level the playing field” and reduce the advantages enjoyed by e-cigs as a consequence of their largely unrestricted marketing. Among the areas for increased regulation of e-cigarettes, the tobacco companies can lobby federal, state, and local governments to ban television and radio broadcasting of e-cig advertising, prohibit online sales of this product category, and proscribe e-cig use in public places. These changes will reduce some of the advantages of e-cigs over tobacco products, thereby presumably slowing the market acceptance.
Government policies for Marijuana (Pot) - Canada - Analysis and Commentary - ...
This presentation will look at medical marijuana as well as the government of Canada goal to legalised marijuana (Pot) in Canada. The discussion will look at areas like revenue, healthcare, enforcement, regulations, etc.
Fried PR: "This is Your Brain on Drugs"
The "Fried Egg" PSA campaign from the 1980s aimed to portray the dangers of drug use by comparing a fried egg to a damaged brain on drugs. It was privately funded through large corporations. While it brought drug issues into the spotlight, it received criticism for using scare tactics and inaccuracies. Later PSAs tried to improve the message but still relied on exaggeration. The egg industry also opposed the initial PSA for negatively associating eggs with drugs. Overall the campaign had some success in raising awareness but saw declining effectiveness over time.
Similar to Cannabis Science & Policy Summit - Day 1 - MacCoun (20)
Will COVID-19 Push Marijuana Legalization Forward or Slow It Down?
Will COVID-19 Push Marijuana Legalization Forward or Slow It Down?
Marijuana / Cannabis| Policy Review and Analysis| Canada| April 2019
Marijuana / Cannabis| Policy Review and Analysis| Canada| April 2019
2019 Election| Legalization of Cannabis (Pot) | Canada | July 2019
2019 Election| Legalization of Cannabis (Pot) | Canada | July 2019
Government policies for Legalizing Marijuana - Canada - Analysis and Commentary
Government policies for Legalizing Marijuana - Canada - Analysis and Commentary
Government policies - Marijuana - Canada - analysis and commentary - july 2017
Government policies - Marijuana - Canada - analysis and commentary - july 2017
Policy Review| Cannabis (Marijuana)| Canada| July 2021
Policy Review| Cannabis (Marijuana)| Canada| July 2021
Government policies for Marijuana (Pot) - Canada - Analysis and Commentary - ...
Government policies for Marijuana (Pot) - Canada - Analysis and Commentary - ...
Recently uploaded
Unlocking the mysteries of reproduction: Exploring fecundity and gonadosomati...
The pygmy halfbeak Dermogenys colletei, is known for its viviparous nature, this presents an intriguing case of relatively low fecundity, raising questions about potential compensatory reproductive strategies employed by this species. Our study delves into the examination of fecundity and the Gonadosomatic Index (GSI) in the Pygmy Halfbeak, D. colletei (Meisner, 2001), an intriguing viviparous fish indigenous to Sarawak, Borneo. We hypothesize that the Pygmy halfbeak, D. colletei, may exhibit unique reproductive adaptations to offset its low fecundity, thus enhancing its survival and fitness. To address this, we conducted a comprehensive study utilizing 28 mature female specimens of D. colletei, carefully measuring fecundity and GSI to shed light on the reproductive adaptations of this species. Our findings reveal that D. colletei indeed exhibits low fecundity, with a mean of 16.76 ± 2.01, and a mean GSI of 12.83 ± 1.27, providing crucial insights into the reproductive mechanisms at play in this species. These results underscore the existence of unique reproductive strategies in D. colletei, enabling its adaptation and persistence in Borneo's diverse aquatic ecosystems, and call for further ecological research to elucidate these mechanisms. This study lends to a better understanding of viviparous fish in Borneo and contributes to the broader field of aquatic ecology, enhancing our knowledge of species adaptations to unique ecological challenges.
ANAMOLOUS SECONDARY GROWTH IN DICOT ROOTS.pptx
Abnormal or anomalous secondary growth in plants. It defines secondary growth as an increase in plant girth due to vascular cambium or cork cambium. Anomalous secondary growth does not follow the normal pattern of a single vascular cambium producing xylem internally and phloem externally.
bordetella pertussis.................................ppt
Bordettela is a gram negative cocobacilli spread by air born drop let
3D Hybrid PIC simulation of the plasma expansion (ISSS-14)
3D Particle-In-Cell (PIC) algorithm,
Plasma expansion in the dipole magnetic field.
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...University of Maribor
Slides from talk:
Aleš Zamuda: Remote Sensing and Computational, Evolutionary, Supercomputing, and Intelligent Systems.
11th International Conference on Electrical, Electronics and Computer Engineering (IcETRAN), Niš, 3-6 June 2024
Inter-Society Networking Panel GRSS/MTT-S/CIS Panel Session: Promoting Connection and Cooperation
https://www.etran.rs/2024/en/home-english/Deep Software Variability and Frictionless Reproducibility
Deep Software Variability and Frictionless ReproducibilityUniversity of Rennes, INSA Rennes, Inria/IRISA, CNRS
The ability to recreate computational results with minimal effort and actionable metrics provides a solid foundation for scientific research and software development. When people can replicate an analysis at the touch of a button using open-source software, open data, and methods to assess and compare proposals, it significantly eases verification of results, engagement with a diverse range of contributors, and progress. However, we have yet to fully achieve this; there are still many sociotechnical frictions.
Inspired by David Donoho's vision, this talk aims to revisit the three crucial pillars of frictionless reproducibility (data sharing, code sharing, and competitive challenges) with the perspective of deep software variability.
Our observation is that multiple layers — hardware, operating systems, third-party libraries, software versions, input data, compile-time options, and parameters — are subject to variability that exacerbates frictions but is also essential for achieving robust, generalizable results and fostering innovation. I will first review the literature, providing evidence of how the complex variability interactions across these layers affect qualitative and quantitative software properties, thereby complicating the reproduction and replication of scientific studies in various fields.
I will then present some software engineering and AI techniques that can support the strategic exploration of variability spaces. These include the use of abstractions and models (e.g., feature models), sampling strategies (e.g., uniform, random), cost-effective measurements (e.g., incremental build of software configurations), and dimensionality reduction methods (e.g., transfer learning, feature selection, software debloating).
I will finally argue that deep variability is both the problem and solution of frictionless reproducibility, calling the software science community to develop new methods and tools to manage variability and foster reproducibility in software systems.
Exposé invité Journées Nationales du GDR GPL 2024
Bob Reedy - Nitrate in Texas Groundwater.pdf
Presented at June 6-7 Texas Alliance of Groundwater Districts Business Meeting
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...Abdul Wali Khan University Mardan,kP,Pakistan
hematic appreciation test is a psychological assessment tool used to measure an individual's appreciation and understanding of specific themes or topics. This test helps to evaluate an individual's ability to connect different ideas and concepts within a given theme, as well as their overall comprehension and interpretation skills. The results of the test can provide valuable insights into an individual's cognitive abilities, creativity, and critical thinking skillsThe debris of the ‘last major merger’ is dynamically young
The Milky Way’s (MW) inner stellar halo contains an [Fe/H]-rich component with highly eccentric orbits, often referred to as the
‘last major merger.’ Hypotheses for the origin of this component include Gaia-Sausage/Enceladus (GSE), where the progenitor
collided with the MW proto-disc 8–11 Gyr ago, and the Virgo Radial Merger (VRM), where the progenitor collided with the
MW disc within the last 3 Gyr. These two scenarios make different predictions about observable structure in local phase space,
because the morphology of debris depends on how long it has had to phase mix. The recently identified phase-space folds in Gaia
DR3 have positive caustic velocities, making them fundamentally different than the phase-mixed chevrons found in simulations
at late times. Roughly 20 per cent of the stars in the prograde local stellar halo are associated with the observed caustics. Based
on a simple phase-mixing model, the observed number of caustics are consistent with a merger that occurred 1–2 Gyr ago.
We also compare the observed phase-space distribution to FIRE-2 Latte simulations of GSE-like mergers, using a quantitative
measurement of phase mixing (2D causticality). The observed local phase-space distribution best matches the simulated data
1–2 Gyr after collision, and certainly not later than 3 Gyr. This is further evidence that the progenitor of the ‘last major merger’
did not collide with the MW proto-disc at early times, as is thought for the GSE, but instead collided with the MW disc within
the last few Gyr, consistent with the body of work surrounding the VRM.
Micronuclei test.M.sc.zoology.fisheries.
Current Ms word generated power point presentation covers major details about the micronuclei test. It's significance and assays to conduct it. It is used to detect the micronuclei formation inside the cells of nearly every multicellular organism. It's formation takes place during chromosomal sepration at metaphase.
Sharlene Leurig - Enabling Onsite Water Use with Net Zero Water
Sharlene Leurig - Enabling Onsite Water Use with Net Zero WaterTexas Alliance of Groundwater Districts
Presented at June 6-7 Texas Alliance of Groundwater Districts Business MeetingThe binding of cosmological structures by massless topological defects
Assuming spherical symmetry and weak field, it is shown that if one solves the Poisson equation or the Einstein field
equations sourced by a topological defect, i.e. a singularity of a very specific form, the result is a localized gravitational
field capable of driving flat rotation (i.e. Keplerian circular orbits at a constant speed for all radii) of test masses on a thin
spherical shell without any underlying mass. Moreover, a large-scale structure which exploits this solution by assembling
concentrically a number of such topological defects can establish a flat stellar or galactic rotation curve, and can also deflect
light in the same manner as an equipotential (isothermal) sphere. Thus, the need for dark matter or modified gravity theory is
mitigated, at least in part.
Thornton ESPP slides UK WW Network 4_6_24.pdf
ESPP presentation to EU Waste Water Network, 4th June 2024 “EU policies driving nutrient removal and recycling
and the revised UWWTD (Urban Waste Water Treatment Directive)”
BREEDING METHODS FOR DISEASE RESISTANCE.pptx
Plant breeding for disease resistance is a strategy to reduce crop losses caused by disease. Plants have an innate immune system that allows them to recognize pathogens and provide resistance. However, breeding for long-lasting resistance often involves combining multiple resistance genes
Recently uploaded (20)
Unlocking the mysteries of reproduction: Exploring fecundity and gonadosomati...
Unlocking the mysteries of reproduction: Exploring fecundity and gonadosomati...
bordetella pertussis.................................ppt
bordetella pertussis.................................ppt
3D Hybrid PIC simulation of the plasma expansion (ISSS-14)
3D Hybrid PIC simulation of the plasma expansion (ISSS-14)
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...
aziz sancar nobel prize winner: from mardin to nobel
aziz sancar nobel prize winner: from mardin to nobel
Deep Software Variability and Frictionless Reproducibility
Deep Software Variability and Frictionless Reproducibility
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...
The debris of the ‘last major merger’ is dynamically young
The debris of the ‘last major merger’ is dynamically young
Sharlene Leurig - Enabling Onsite Water Use with Net Zero Water
Sharlene Leurig - Enabling Onsite Water Use with Net Zero Water
The binding of cosmological structures by massless topological defects
The binding of cosmological structures by massless topological defects
Cannabis Science & Policy Summit - Day 1 - MacCoun
- 1. Cannabis revenues as temptation goods Rob MacCoun Stanford Law School
- 2. Jon’s talk: Some key points National legalization, probably on the alcohol model, is very likely Long-run consumption may (at least) double Prices matter Quantity consumed matters more than how many consume Lots of policy levers – are we using them to learn what works? 5/18/2016MacCoun 2
- 3. Nat’l legalization inevitable? Still 46 states to go (45.5 since DC halfway there) President Cruz might put a stop to it. So might President Ryan. Even President Clinton. Or Republican-led House and Senate. CO and WA and OR and AK could “blow it” If consumption or harms start “spiraling out of control” Headline: “Carload of Utah high school football players in fatal crash after drug holiday” 5/18/2016MacCoun 3
- 5. True, but boomer’s support dropped a lot in 1980-1990 5/18/2016MacCoun 5
- 6. Easing budget pressures could reduce push for pot revenues 5/18/2016MacCoun 6
- 7. Effects in CO, WA? Caveat emptor If you want to dismiss opponents’ claims, ought to hold yourself to same standard of evidence May take many years to assess effects Retailers have many steps to get licensed Legal production has to reach scale Short term “nostalgia” and curiosity purchases Prices may fall over time (perhaps a lot) Dutch marijuana use told different stories in 1979 vs. 1992 vs. 2008 5/18/2016MacCoun 7
- 8. On doubling With respect to prevalence, we know what a doubling looks like: 1979 My students are usually stunned to learn this. With respect to consumption, would be entirely new territory My students already have seen a lot more daily and heavy use than my cohort saw. Jon suggests we might see 40 billion additional hours of intoxication 5/18/2016MacCoun 8
- 9. Fundamental tradeoff Legalization reduces average harm per dose (medical, crime, etc.) Legalization increases number of doses consumed Net effect (harm/dose x doses) is unknown 5/18/2016MacCoun 9
- 10. Legalization and average harm In Drug War Heresies, Reuter and I predicted that after legalization, the average user would be a less risky user. Influx of users who wouldn’t use because it was illegal. No longer sure we were right. We were focused on prevalence (who uses) Might be swamped by increasing riskiness of existing users and new products (vaping, dabs, edibles) 5/18/2016MacCoun 10
- 11. 5/18/2016MacCoun 11 What strains with the High Times Cannabis Cup?
- 12. Cannabis Cup 5/18/2016MacCoun 12 All finalists exceed federal potency estimates Trend toward higher THC 1st place winners have higher THC and lower CBD
- 13. SimSemilla model Users (count) • Occasional • Monthly • Weekly • Daily Grams/day (per type) Days-used distribution Grams/year distribution Harm incidents per year: • Overall • by User type • Gini & skew Grams/day distribution p(harm|dose) Dose-harm function: • Ceiling • Shape • Threshold 5/18/2016MacCoun 13